Ordering Human CD34+CD10-CD19+ Pre/pro-B-cell and CD19- Common Lymphoid Progenitor Stages in Two Pro-B-cell Development Pathways
Overview
Authors
Affiliations
Studies here respond to two long-standing questions: Are human "pre/pro-B" CD34(+)CD10(-)CD19(+) and "common lymphoid progenitor (CLP)/early-B" CD34(+)CD10(+)CD19(-) alternate precursors to "pro-B" CD34(+)CD19(+)CD10(+) cells, and do the pro-B cells that arise from these progenitors belong to the same or distinct B-cell development pathways? Using flow cytometry, gene expression profiling, and Ig V(H)-D-J(H) sequencing, we monitor the initial 10 generations of development of sorted cord blood CD34(high)Lineage(-) pluripotential progenitors growing in bone marrow S17 stroma cocultures. We show that (i) multipotent progenitors (CD34(+)CD45RA(+)CD10(-)CD19(-)) directly generate an initial wave of Pax5(+)TdT(-) "unilineage" pre/pro-B cells and a later wave of "multilineage" CLP/early-B cells and (ii) the cells generated in these successive stages act as precursors for distinct pro-B cells through two independent layered pathways. Studies by others have tracked the origin of B-lineage leukemias in elderly mice to the mouse B-1a pre/pro-B lineage, which lacks the TdT activity that diversifies the V(H)-D-J(H) Ig heavy chain joints found in the early-B or B-2 lineage. Here, we show a similar divergence in human B-cell development pathways between the Pax5(+)TdT(-) pre/pro-B differentiation pathway that gives rise to infant B-lineage leukemias and the early-B pathway.
Kulp M, Larghero P, Alten J, Cario G, Eckert C, Caye-Eude A Leukemia. 2023; 37(6):1216-1233.
PMID: 37100882 PMC: 10132433. DOI: 10.1038/s41375-023-01895-z.
Abdulla Z, Al-Bashir S, Alzoubi H, Al-Salih N, Aldamen A, Abdulazeez A Pathogens. 2023; 12(2).
PMID: 36839601 PMC: 9967364. DOI: 10.3390/pathogens12020329.
CD34CD10CD19 Cells in Patients with Unhealthy Alcohol Use Stimulate the M2b Monocyte Polarization.
Asai A, Tsuchimoto Y, Ohama H, Nishikawa H, Chopra A, Higuchi K Cells. 2022; 11(17).
PMID: 36078108 PMC: 9454773. DOI: 10.3390/cells11172703.
B cell targeting in CAR T cell therapy: Side effect or driver of CAR T cell function?.
Chen G, Melenhorst J, Tan K Sci Transl Med. 2022; 14(650):eabn3353.
PMID: 35731887 PMC: 9284935. DOI: 10.1126/scitranslmed.abn3353.
Watt S, Hua P, Roberts I Int J Mol Sci. 2022; 23(7).
PMID: 35409034 PMC: 8999121. DOI: 10.3390/ijms23073675.